Saad Z. Usmani, MD
LightNews LightNews
banner
szusmani.bsky.social
Saad Z. Usmani, MD
@szusmani.bsky.social
540 followers 73 following 29 posts
Views are my own.
Posts Replies Media Videos
Reposted by Saad Z. Usmani, MD
mskdeptofmed.bsky.social
Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma.

🗓️ Thursday, September 18 | 4:40 p.m. EDT

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
September 18, 2025 at 6:02 PM
Reposted by Saad Z. Usmani, MD
mskdeptofmed.bsky.social
Coming up at #IMS25: Join MSK's Myeloma Service Chief @szusmani.bsky.social to learn about current challenges in #multiplemyeloma relapse & future research needed to overcome them. #mmsm

🗓️ Friday, September 19 | 9:40 a.m. EDT

@mskcancercenter.bsky.social @myeloma-society.bsky.social
September 19, 2025 at 12:03 PM
Reposted by Saad Z. Usmani, MD
mskdeptofmed.bsky.social
At #IMS25, Dr. Francesco Maura will present new research on the genomics that define neoplastic transformation in #multiplemyeloma precursor conditions. #mmsm

🗓️ Saturday, September 20 | 9:20 a.m. EDT

@mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social
September 20, 2025 at 12:01 PM
Reposted by Saad Z. Usmani, MD
mskdeptofmed.bsky.social
MSK is headed to Toronto for #IMS25! Stay tuned for posters and presentations that are advancing #multiplemyeloma research and treatments. #mmsm

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
myeloma-society.bsky.social Myeloma Society @myeloma-society.bsky.social · Sep 12
⏳We are less than one week away from #IMS25 in Toronto! Get ready for world-class insights, valuable networking, and meaningful innovation. If you can’t join us in person, you can still take part virtually. 💻 Register now ➡️ rb.gy/139j28
September 13, 2025 at 2:52 PM
Reposted by Saad Z. Usmani, MD
mskdeptofmed.bsky.social
MSK experts have arrived at #IMS25! Join Dr. Francesco Maura to learn about genomic drivers of resistance to anti-BCMA immunotherapies in #multiplemyeloma. #mmsm

🗓️ Wednesday, September 17 | 11:10 a.m. EDT

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
September 17, 2025 at 12:03 PM
Reposted by Saad Z. Usmani, MD
mskdeptofmed.bsky.social
At #IMS25, Dr. Carlyn Tan will share new data on early mortality associated with real-world bispecific antibody therapy for relapsed/refractory #multiplemyeloma.

🗓️ Wednesday, September 17 | 12:14 p.m. EDT

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
September 17, 2025 at 2:04 PM
Reposted by Saad Z. Usmani, MD
onclive.bsky.social
Sign up to read exclusive expert insights on key abstracts to watch at #IMS25! @szusmani.bsky.social @mskcancercenter.bsky.social @myeloma-society.bsky.social #mmsm
www.onclive.com/view/experts...
September 11, 2025 at 2:21 PM
Reposted by Saad Z. Usmani, MD
mskcancercenter.bsky.social
Join Dr. @szusmani.bsky.social as he presents research on "Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed #MM (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study" at #ASCO25. @ascocancer.bsky.social
June 2, 2025 at 1:26 PM
Reposted by Saad Z. Usmani, MD
mskcancercenter.bsky.social
"The phase 3 CEPHEUS trial previously demonstrated improved efficacy outcomes with DVRd vs VRd in patients with TIE or transplant-differed NDMM," shares myeloma specialist
@szusmani.bsky.social during his session at #ASCO25.

@ascocancer.bsky.social
June 2, 2025 at 3:22 PM
Reposted by Saad Z. Usmani, MD
onclive.bsky.social
D-VRd Retains Its Role as a Standard of Care for Transplant-Ineligible Multiple Myeloma @ascocancer.bsky.social @mskcancercenter.bsky.social @szusmani.bsky.social #ASCO25 #mmsm www.onclive.com/view/d-vrd-r...
D-VRd Retains Its Role as a Standard of Care for Transplant-Ineligible Multiple Myeloma
D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.
www.onclive.com
June 2, 2025 at 8:57 PM
Reposted by Saad Z. Usmani, MD
mskdeptofmed.bsky.social
Congrats to Mark G. Kris, Kenneth Offit, David G. Pfister, and
@szusmani.bsky.social on being inducted into the 13th Giants of Cancer Care® class by @onclive.bsky.social! This award honors leading physicians who are advancing #cancerresearch. @mskcancercenter.bsky.social
Learn more: bit.ly/42Ox58M
May 7, 2025 at 4:57 PM
Reposted by Saad Z. Usmani, MD
imfmyeloma.bsky.social
❤️ Thank you, Dr. Usmani for continuing to support #MyelomaICE!
March 7, 2025 at 3:09 PM
szusmani.bsky.social
Dear all, putting in a plug for the International Myeloma Foundation Iceland Cycling Expedition 2025 below. Thanks for your generosity last year, many of you contributed to its success. Every donation and any amount counts.
@imfmyeloma.bsky.social
fundraise.myeloma.org/fundraiser/5...
Iceland Cycling Expedition
{{MetaTags.description}}
fundraise.myeloma.org
March 7, 2025 at 2:04 PM
Reposted by Saad Z. Usmani, MD
aksimhal.bsky.social
1/ 🚨New research alert! 🚨Our study in Blood Cancer shows that high WEE1 expression is an independent predictor of poor survival in multiple myeloma, with @joedeasy.bsky.social, @malinhultcrantz.bsky.social, @szusmani.bsky.social, and the rest of the @mskcancercenter.bsky.social team! 🧵👇#MyelomaSky
February 21, 2025 at 7:36 PM
Reposted by Saad Z. Usmani, MD
mskcancercenter.bsky.social
NEW in @natmedicine.bsky.social: Results from a phase 3 clinical trial led by MSK's #myeloma specialist & cellular therapist @szusmani.bsky.social. Learn more: www.nature.com/articles/s41...
mskdeptofmed.bsky.social MSK Department of Medicine @mskdeptofmed.bsky.social · Feb 6
A phase 3 clinical trial led by @szusmani.bsky.social found that a combination of four therapies significantly improved outcomes for people with transplant-ineligible newly diagnosed #multiplemyeloma. #mmsm @mskcancercenter.bsky.social @natmedicine.bsky.social
www.nature.com/articles/s41...
February 6, 2025 at 4:15 PM
szusmani.bsky.social
Quadruplets induction regimens are the established standards of care now in newly diagnosed MM, just out 🎉👇🏽
#MyelomaSky

@mskcancercenter.bsky.social
@imfmyeloma.bsky.social
@themmrf.bsky.social
@healthtreeorg.bsky.social

www.nature.com/articles/s41...
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study - Nature Medicine
In the phase 3 CEPHEUS trial, patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma were treated with subcutaneous daratumumab plus bortezomib, lenalidomide and d...
www.nature.com
February 6, 2025 at 12:00 PM
Reposted by Saad Z. Usmani, MD
drmhb.bsky.social
Thanks to @szusmani.bsky.social for donating 🙌🏾🙌🏾🙌🏾🥳🥳🥳 to support multiple myeloma cancer research @ give.themmrf.org/fundraiser/5...
2024 MM4MM: Mount Kilimanjaro
{{MetaTags.description}}
give.themmrf.org
December 18, 2024 at 4:21 AM
Reposted by Saad Z. Usmani, MD
mskdeptofmed.bsky.social
This is your last chance to see incredible research at the #ASH24 poster session today! Don't miss posters by Drs. Gunjan Shah, Carlyn Rose Tan, & Pallawi Torka. @mskcancercenter.bsky.social @szusmani.bsky.social

6-8 p.m. PST
https://buff.ly/3ZLbSey
https://buff.ly/3OOjjeG
https://buff.ly/3Vum0Wv
December 10, 2024 at 12:00 AM
Reposted by Saad Z. Usmani, MD
mskcancercenter.bsky.social
Congratulations to MSK's Dr. Urvi Shah for being awarded the @ash-hematology.bsky.social David M. Goldenberg Clinical Research Training Institute Award for her work on research that shows that a high-fiber, plant-based dietary intervention may delay progression #MGUS/#SMM to #MM.

#ASH24 #ASHKudos
December 8, 2024 at 11:24 PM
Reposted by Saad Z. Usmani, MD
mskcancercenter.bsky.social
Dr. @szusmani.bsky.social presents on “Working with Data Hub Data and Network PIs to Develop Evidence that Changes Practice in Multiple Myeloma: The COSMIC Study as Proof of Concept” that is part of the ASH Research Collaborative Multiple Myeloma Network at @ash-hematology.bsky.social.

#ASH24
December 8, 2024 at 2:13 AM
szusmani.bsky.social
Please join us now #ASH24
#MyelomaSky
ASH RESEARCH COLLABORATIVE MULTIPLE MYELOMA NETWORK: ACCELERATING RESEARCH AND COLLABORATIVE CLINICAL CARE THROUGH REAL-WORLD EVIDENCE GENERATION
December 7, 2024, 4:00 p.m. - 5:30 p.m.
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26
December 8, 2024 at 12:22 AM
Reposted by Saad Z. Usmani, MD
mskcancercenter.bsky.social
#ASH24: Join myeloma specialist Dr. @szusmani.bsky.social for his presentation on "Working with Data Hub Data and Network PIs to Develop Evidence that Changes Practice in Multiple Myeloma: The COSMIC Study as Proof of Concept" today at 4pm PT at @ash-hematology.bsky.social.

bit.ly/49vscmW
December 7, 2024 at 6:14 PM
Reposted by Saad Z. Usmani, MD
mskdeptofmed.bsky.social
Join Kylee Maclachlan for the presentation "Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease."

2:15 pm PST. #ASH24 @mskcancercenter.bsky.social
@szusmani.bsky.social @ash-hematology.bsky.social
buff.ly/4f6J3gP
December 7, 2024 at 7:16 PM
Reposted by Saad Z. Usmani, MD
ash.hematology.org
☀️ Awaken your inner poet and write your best haiku about #ASH24 or #hematology! That's 3 lines in a 5-7-5 syllable pattern.

Post now through Tuesday afternoon and include #ASHaiku. You might get included in a highlights post!

🛑Remember, there's only one H in #ASHaiku!

#HemeSky #Hematology
December 5, 2024 at 1:10 PM
szusmani.bsky.social
and finally, the #ASH24 #MyelomaSky **Basic/Translational Abstracts:
1019 A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
ash.confex.com/ash/2024/web...
Paper: A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
ash.confex.com
December 5, 2024 at 8:55 PM